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INTRODUCTION
 Fertility of females resides in the pool of 
primordial follicles, they are born with. Amongst 
these, 30 to 50 follicles are recruited with each 
menstrual cycle leading to decline in fertility after 
the age of 30 years.1 In cases of infertility, evaluation 
of ovarian reserve (OR) is essential to optimize 
protocol for assisted reproductive technique (ART) 
and prediction of response to counsel the couple.2
 The likelihood of successful ovarian response is 
usually assessed on age; most dependable variable 
affecting results of treatment. However, even 
within comparable ages, wide variability has been 
reported,3 concluding age as a weak reflector of 
ovarian pool. Thus other markers such as Follicle 
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Anti Mullerian Hormone: Ovarian response indicator in 
young patients receiving Long GnRH Agonist Protocol
 for Ovarian Stimulation
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ABSTRACT
Objective: Anti Mullerian hormone (AMH) is gaining place as ovarian marker, chiefly in infertility assistance. 
We explored its correlation with oocytes retrieval after long GnRH agonist protocol for stimulation, in 
younger and older infertile population. 
Methods: This retrospective analysis compiled data of 166 females, receiving ICSI treatment from June 
2014 to March 2015.  Serum FSH, LH, Estadiol, AMH and antral follicle count were assessed. Outcomes were 
measured as good (5 to 19 oocytes) and bad responders. 
Results: Higher discriminatory power of AMH (AUROC; 0.771; p < 0.05) was seen in comparison to FSH 
(0.692; p < 0.05) and AFC (0.690; p < 0.01). AMH reported strongest association with oocyte retrieved (odds 
ratio of 15.06). Subgroup analysis reported 68.6 % risk of bad response with AMH levels of less than 1.37ng/
ml. This association was observed more significant in young infertile patients <35 year of age (r=0.245; 
p=0.012) versus older population >35 year (r=0.169; p>0.05). 
Conclusion: Our study reaffirms that serum AMH correlates well with oocytes retrieved, particularly 
in females younger than 35 years. We suggest incorporation of AMH in baseline assessment of infertile 
females, who are falsely advised to postpone interventions based on their age and normal FSH levels.
KEY WORDS: Anti Mullerian Hormone, Assisted Reproductive Technology, Ovarian stimulation, Ovarian 
reserve.
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stimulating hormone (FSH), luteinizing hormone 
(LH), Inhibin, Estradiol (E2), ovarian volumes and 
antral follicle count (AFC) have been deployed to 
predict the response.4
 A rise in FSH levels is most widely recognized 
hallmark of reduction in the OR.5 It may not be 
the best option as it suffers inter and intra cyclic 
fluctuations.6 FSH production is further deranged 
in patients receiving oral contraceptive pills, in 
polycystic ovarian syndrome (PCOS) and pituitary 
tumors.7 Similarly, AFC is assessed for estimation 
of dosage and in predicting response to stimulation 
but operators’ variability, mechanical consistency 
and previous history of ovarian surgery are its main 
limitations.
 Anti Mullerian hormone (AMH) is recently 
considered as a unique OR marker, solely 
secreted by granulosa cells and accurately reflects 
primordial follicle.8 It is a glycoprotein dimer 
belonging to TGF-β family and has potential role 
in the maintenance of OR.9,10 Drop in serum AMH 
reliably indicates decline in ovarian function. 
Hence, it is now being used to assess ovarian 
injury induced by chemotherapy, radiation therapy 
or ovarian surgery.11 It correlates well with the 
number of oocytes retrieved after stimulation and 
reflects excessive follicular growth in women with 
ovarian hyper stimulation syndrome (OHSS) and 
PCOS.12,13 These oocytes retrieved after stimulation, 
reflects availability of embryos for transfer and 
hence an optimum response to Long GnRH agonist 
protocol is said to achieve by retrieval of at least five 
oocytes.14
 Therefore, this study aimed to assess reliability 
of various markers (like FSH, AFC and AMH) in 
predicting response to intra-cytoplasmic sperm 
injection (ICSI). Our results propose that regarding 
number of oocytes retrieved, AMH is a better 
predictor in comparison to age, BMI, AFC and FSH, 
particularly in younger infertile population (20 to 
35 years).
METHODS
 In this retrospective cross-sectional analysis, 
data of 166 infertile females was collected from 
Australian Concept Infertility Medical Centre 
(ACMIC). Females booked for the first ICSI 
treatment from June 2014 to March 2015, aged 20 to 
42 year, with regular menstrual cycles, no endocrine 
disorders or prior ovarian surgery, were included 
while PCOS were excluded from study. Ethical 
clearance was obtained from ACMIC. Written 
consent was waived by Institutional review board 
as retrospective design could not alter the clinical 
decision made during ICSI treatment. Furthermore, 
patients’ records were anonymized prior to analysis 
to maintain confidentiality. Serum samples were 
collected on days 2–3 of menstrual cycles one 
month prior to ICSI treatment. Supernatant fluid 
was used for the assays maintained at temperature 
from 2-8 ºC.
 AMH was measured using AMH Gen 11 Elisa 
reagent kit (Beckman coulter, ref a79765). FSH 
and LH were measured using Elecsys reagent 
kit following the manufacturer protocol. AFC 
assessment was carried out on day 3, using an 
Aloka SSD-1000 (Japan) with a 5 MHz transvaginal 
probe. Follicles measuring <10 mm in diameter 
were counted in both ovaries to determine the 
cohort with an inter observer CV <5%.
 1 mg of subcutaneous Buserelin Acetate 
(Suprefact) was initiated on day 21 to achieve 
adequate ovarian suppression, followed by 
recombinant FSH (Gonal-f) or hMG (Menogon). 
hCG (Ovitrelle, 250 μg, Merck Serono) was 
administered on an adequate E2 response and two 
Table-I: Descriptive statistics of whole cohort and according to responder category.
Variables Whole Study Population Good Responder (5-19 oocyte count) Bad Responder (<5, >19 oocytes)
 n =166 n =90 n = 76
  Mean ± SD
Age (year) 33.6  ± 6.03 31.7 ± 5.4 35.6 ± 6.0
BMI (kg/m2) 29.3 ± 5.41 28.70 ± 5.4 29.8± 5.3
FSH (IU/L) 8.5  ± 4.9 6.9 ± 3.2 10.2 ± 5.7*
LH (IU/L) 6.9 ± 1.057 6.5 ± 1.7 7.4 ± 1.4
AMH (ng/ml) 1.6 ± 1.3 2.3 ± 0.7 1.4 ± 0.5*
AFC 9.3 ± 4.3 10.6 ± 5.1 7.9 ± 2.6 *
Estradiol (pg/ml) 46.95 ± 6.3 48.0 ± 6.78 45.0 ± 7.3
Data expressed as Mean ± S.D. Mann Whitney U test was used to compare the difference between groups.
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or more follicles measuring ≥18 mm. Oocytes were 
retrieved trans-vaginally and sperms were injected. 
Embryos were transferred into uterus after 72 hours 
of insemination. Luteal phase support was given by 
Pregnyl 1500 IU. Clinical pregnancy was confirmed 
by sonographic evidence of an intrauterine 
gestational sac. 
 Main outcome was measured as good 
responders having at least 5 to 19 oocytes 
retrieved while bad responders had either less 
than 5 or more than 19 oocytes retrieved. Positive 
pregnancies were not considered as the outcome 
due to limited size of sample and inclusion of 
cases with male infertility.
 Data was analyzed by SPSS version 19 and 
comparison of variables was done by Mann 
Whitney U test. Logistic regression determined the 
predictive value for ovarian response while AUROC 
analysis was used to see the predictive accuracy of 
FSH and AMH. Spearman bivariate correlation was 
applied between AMH and FSH. P value of <0.05 
was considered significant.
RESULTS
 The mean BMI, FSH and AMH levels of one 
hundred and sixty-six infertile females recruited 
in this study is summarized in Table-I. While 
grouping them according to oocytes retrieved, 
both AMH and AFC were significantly low in bad 
responders (p < 0.05) whereas FSH was raised 
(p <0.05).
 Table-II compares the groups according to 
AMH cut off, FSH and age. One hundred fifty 
two females reported low AMH and out of these, 
only 47.5% responded well while in higher AMH 
category, 85.7% females had a good response. In 
these groups, significant difference in AMH was 
observed (p<0.01) whereas LH, FSH and AFC had 
insignificant difference. On FSH stratification, 
significant difference in the levels of LH, AMH 
and AFC (p <0.05) was observed. Good response 
was reported by 62.2% of normal while 30.0% 
of raised FSH group. In age segregated groups, 
insignificant variance was seen for AMH, LH and 
FSH. 
 Next, on binary logistic regression, unadjusted 
model reported that females with low AMH were 
6.66 times more likely to have a poor response than 
raised FSH (3.66 times). After adjusting for age and 
BMI, AMH gave even stronger positive significant 
association with the responder group [OR 15.06 
(2.83- 80.01)] versus FSH [OR 4.12 (1.12-9.86)] 
(Table-III). 
Zehra Jamil et al.
Table-III: Logistic Regression Analysis for FSH, AMH and AFC.
Variables Unadjusted Adjusted for Age and BMI
 OR 95% C.I  OR 95% C.I
  Lower Upper  Lower Upper
FSH 3.66* 1.85 7.24 4.12* 1.72 9.86
AMH 6.66* 1.44 30.80 15.06* 2.83 80.01
AFC 0.79* 0.70 0.89 0.81* 0.72 0.90
Table-II: Biophysical and Biochemical Variables on the basis of AMH, FSH and Age Category.
 Age AMH FSH
 35-42 year 20-35 year Normal >1.37ng/ml Low <1.37ng/ml Normal < 11 IU/L High >11 IU/L
 n = 60 n =106  n =14  n = 152  n =106 n = 60
 Mean ± SD
Age (year) 40.2 ± 3.5 29.9±3.4* 33 ± 8.9 33.6 ± 5.7 32.3 ±5.7 36 ± 6.0
BMI (kg/m2) 30.1 ± 5.2 28.8±5.5 33.4 ± 3.3 28.9  ± 5.4* 28.9 ± 5.1 30 ± 5.6
FSH (IU/L) 9.1 ± 5.3 8.1 ± 4.6 5.9 ± 3.3 8.8 ± 4.5 6.1± 1.9 13 ± 5.5*
LH (IU/L) 7.3 ± 2.5 6.8 ± 1.1 4.3 ± 2.5 7.2 ± 1.5 4.5 ± 2.4 11.3 ± 4.4*
AMH (ng/ml) 1.5 ± 0.8 2.0 ± 0.3* 2.8 ± 1.1 0.7 ± 0.3* 2.2 ± 0.4 1.2 ± 0.5*
AFC 8.4 ± 2.9 9.8 ± 4.8 8.0 ± 1.9 9.4 ± 4.4 8.6 ± 4.6 9.7 ± 4.0*
Good Responder%  36.6 58.5 85.7 47.4 62.2 30.0
Bad Responder % 63.3 41.5  14.2 52.6 37.7 70.0
Data expressed as Mean ± S.D. and frequency and percentage wherever applicable.
Mann Whitney U test was used to compare the difference between groups.  *p<0.05 considered significant.
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 Fig.1 presents correlation of AMH and FSH with 
oocytes retrieved in various age groups. AMH 
depicted stronger positive association in patients 
<35 year of age (r=0.245; p=0.012) versus patients 
>35 year (r=0.169; p>0.05). FSH depicted negative 
correlation that was likewise higher in patients 
<35 year of age (r=-0.415; p<0.001). In addition, 
significant negative correlation with bad responders 
was observed between the oocyte retrieval and 
AMH (r = -0.468, p <0.001), whereas significant 
positive correlation was seen with FSH (r = 0.332, p 
< 0.001). 
 Later, ROC analysis observed the discriminatory 
power of AMH along with FSH and AFC in two 
responder groups (Table-III). The AUROC for AMH 
was highest (0.771; p < 0.05) in terms of accurately 
discriminate between good and bad responders. 
FSH and AFC had a lower discriminatory power 
(0.692 and 0.690 respectively; p < 0.05). The AMH 
cut-off levels were calculated by the online software 
MedCalc15 for poor ovarian response. A value of 
1.37ng/ml was calculated, with a specificity of 75% 
and a sensitivity of 90% to exhibit higher ability to 
discriminate between good and bad responders 
in all the groups. Serum AMH levels of less than 
1.37ng/ml was associated with bad response while 
that of higher than 1.37ng/ml correlated better 
ovarian reserve. 
DISCUSSION
 Young females are often advised to postpone 
infertility treatment based on their age and 
FSH levels. Hence, we explored strength of 
biomarkers including recently acclaimed AMH in 
discriminating between good and bad responder. 
Furthermore, we analyzed ovarian response in 
sub-groups segregated on the bases of age, FSH 
levels and AMH cut-off values calculated in our 
population.
 In this study, we report significant correlation of 
oocytes retrieved with FSH, AMH and AFC while 
no association with age, BMI or LH. In comparison 
to FSH and AFC, AMH had a superior role as a solo 
marker of response. The AUROC for AMH was 
significantly higher than FSH and AFC (p <0.05). 
Our results revealed that 85.7% patients with normal 
AMH retrieved more than 5 oocytes. Furthermore, 
in unadjusted models of binary logistic regression, 
low AMH showed highest ability to identify bad 
responder as compared to raised FSH or AFC (6.66 
Anti Mullerian Hormone
Fig.1: Correlation of Serum AMH (A) and Serum FSH (B) with the number of oocyte retrieved after stimulation. 
Patients grouped according to ages between 20 to 35 year and 35 to 42 year. 
times and 3.66 times respectively). Undoubtedly, 
AFC assessment is substantial to monitor infertility 
treatment however, operator’s variability is its 
limitation.16 As blood tests have marked advantages 
over ultrasound for primary care physicians, AMH 
has a greater efficiency over AFC, especially in 
setups where high class technology is not feasible.
 While comparing AMH with the most commonly 
used marker FSH, segregation on the basis of 
FSH showed significant inverse correlation with 
AMH (Table-II). Therefore, we suggest AMH as 
its substitute in cases of deranged FSH production 
as discussed earlier. Being an “acyclic” marker, 
AMH assessment is considered reliable anytime 
throughout menstrual cycle17 although few studies 
do report converse findings.18
 To further reinforce our results, AMH cut-off 
value for our population was calculated as 1.37ng/
ml with the strength of 75% specificity and 90% 
sensitivity to correctly predict the response. We 
found that 87% patients having more than 1.37ng/
ml AMH reported higher oocyte retrieval. Similarly, 
mean AMH of patients who conceived on ICSI was 
observed as 1.78 ± 0.95ng/ml. However, due to the 
limitation of sample size and inclusion of couples 
with male infertility, we cannot debate on wider 
role of AMH in predicting pregnancy outcomes. 
Various cut-off are reported across the globe. An 
Indian study has reported serum AMH levels of 
less than 1.4ng/ml as suggestive of poor ovarian 
response to stimulation.19 Here, it is important 
to emphasize that these cut-offs need to be used 
with caution as in our study we witnessed one 
patient reporting good response even with serum 
AMH of 0.6ng/ml. European study quoted AMH 
levels of as low as 0.8 µg/l as sufficient to reflect 
healthy ovarian response.20 This might be explained 
as although low AMH reflects decline in OR, but 
even few oocyte of good quality may still respond 
to gonadotropin stimulation. Thus, we advocate its 
capability in counselling infertile couples, selecting 
treatment protocol and tentatively predicting 
chances of pregnancy. 21
 Next, we assessed AMH as a predictor of oocyte 
retrieval in two different groups based on age. 
In our study there was a stronger correlation in 
patients younger than 35 years (p<0.001, Fig.1 A 
and B). This further supports role of AMH to predict 
ART outcome in younger population that might 
be misjudged due to early age and a normal FSH. 
Studies do report that in population of similar age 
group, wide variations of OR have been testified in 
individuals.3 This explains the variation observed 
in AMH levels but its assessment along with other 
baseline investigations seems to be of additional 
value in screening young infertile patients with 
a decreased OR. Contrary to this, David H et al. 
reported significant correlation of AMH and oocyte 
retrieval in older infertile women.22 This difference 
could possibly be due to population stratification or 
selection criteria. Our study further reports similar 
results between FSH levels and oocyte retrieval as 
it was likewise found to correlate better in younger 
population (p<0.001, Fig.1 A and B). On the other 
hand, AFC showed higher correlation in the older 
group. Our results reported insignificant difference 
in AMH of patients with varied BMI, thus 
suggesting that it reflects true ovarian response 
irrespective of the patient’s BMI as also supported 
by earlier work.23
 In conclusion, we support the role of AMH in 
reflecting the number of oocytes collected for 
successful ART. For the first time, we are reporting 
AMH levels in Pakistani infertile population 
and predict a cut-off value of 1.37ng/ml that 
discriminate good and bad responders. We strongly 
suggest incorporation of AMH evaluation in 
baseline assessment of ovarian reserve, especially 
in younger infertile patients as timely IVF treatment 
can improve the pregnancy outcomes in these 
populations. As our sample size was limited and 
localized, further longitudinal studies are required 
to reassess the cut-off values. Furthermore, studies 
focusing on association of serum AMH with viable 
pregnancy outcomes will increase the support for 
AMH as a predictive marker of live births in ART 
clinics.
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